Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Focus on factors.

P McDaniel1

  • 1Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.

Journal of Intravenous Nursing : the Official Publication of the Intravenous Nurses Society
|February 19, 2002
PubMed
Summary

Recombinant factor VIII concentrates have improved hemophilia A treatment by eliminating viral contamination risks. This review covers historical and current therapies for inherited bleeding disorders, including complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dentists' Adoption of Silver Diamine Fluoride among 1- to 5-Year-Old Children in North Carolina.

JDR clinical and translational research·2020
Same author

Following the course of malaria treatment by detecting parasite lactate dehydrogenase enzyme.

British journal of haematology·2001
Same author

Nonaccredited medical education in the United States.

The New England journal of medicine·2000
Same author

Human ehrlichiosis in Thailand.

Lancet (London, England)·1997
Same author

Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea.

The American journal of the medical sciences·1992
Same author

Purification of rabbit antispermine antiserum by affinity chromatography.

Research communications in chemical pathology and pharmacology·1979

Area of Science:

  • Hematology
  • Coagulation Disorders
  • Factor Replacement Therapy

Background:

  • Hemophilia A treatment historically relied on blood products with viral contamination risks.
  • Recombinant factor VIII concentrates offer a safer alternative for hemophilia management.
  • Inherited coagulopathies encompass various bleeding disorders requiring specialized care.

Purpose of the Study:

  • To provide a historical overview of hemophilia treatment.
  • To discuss current therapeutic strategies for hemophilia and other inherited coagulopathies.
  • To address complications and patient management challenges in factor replacement therapy.

Main Methods:

  • Literature review of historical and current treatment modalities.
  • Analysis of safety and efficacy data for recombinant factor VIII.
  • Discussion of patient management issues and therapy complications.

Main Results:

  • Recombinant factor VIII has significantly reduced viral transmission risks in hemophilia A.
  • Current treatments offer improved bleeding control and quality of life for patients.
  • Management of inherited coagulopathies requires a comprehensive approach.

Conclusions:

  • Recombinant factor VIII represents a major advancement in hemophilia A therapy.
  • Effective management of inherited bleeding disorders involves understanding historical context and current options.
  • Addressing therapy complications and patient management is crucial for optimal outcomes.

Related Experiment Videos